(redirected from relapsing)
Also found in: Dictionary, Thesaurus, Medical, Legal, Idioms, Wikipedia.
Related to relapsing: relapsing fever


the return of ill health after an apparent or partial recovery
Collins Discovery Encyclopedia, 1st edition © HarperCollins Publishers 2005
The following article is from The Great Soviet Encyclopedia (1979). It might be outdated or ideologically biased.



a new exacerbation of a disease during remission after an apparent recovery. In the case of a latent chronic infection, for example, brucellosis, pneumonia, and erysipelas, a relapse may be caused by inadequate immunity, chilling, or the supervention of a secondary infection. It may also be caused by a faulty diet, for example, with colitis, or by the cyclical nature of the disease itself (malaria, relapsing fever). The pathogenic microflora of the body is usually activated as a result of a relapse. A repeated infection caused by the same microorganisms is called a reinfection.

The pathogenesis of a relapse of a noninfectious disease is caused by shock, for example, with eczema, by vascular disorders, by regular malignant growth, and by inadequate treatment, for example, by the incomplete removal of a tumor. The pathogenesis of a relapse is sometimes unknown, for example, with familial Mediterranean fever and schizophrenia.

The clinical symptoms of a relapse may resemble or differ from the onset of a disease as a result of both the nature of the disease and the prescribed treatment. A relapse is sometimes more severe than the first attack of a disease and is more difficult to treat, as in the case of a relapse of acute leukemia. A relapse may be accompanied by complications, for example, intestinal bleeding in typhoid. Relapses are common to some diseases, for example, chronic dysentery. Treatment and preventive methods for relapses are usually the same as for the original disease.


The Great Soviet Encyclopedia, 3rd Edition (1970-1979). © 2010 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
Daily corticosteroids reduce infection associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial.
That boredom was reported as being an important factor in relapsing was not particularly surprising, although it was somewhat unexpected that it was noted as one of the most important reasons.
Whether we are likely to see the reemergence of this disease is difficult to predict because we do not understand relapsing fever borreliae and their complex host interactions.
AVONEX is the world's leading treatment for relapsing forms of multiple sclerosis.
At 24 months, the frequently relapsing nephrotic syndrome (FRNS)-free rates were 56.2% and 50.8% in the groups, respectively (hazard ratio, 0.86), Norishige Yoshikawa, Ph.D., reported in a late-breaking poster at Kidney Week 2013.
Genzyme said on Wednesday that it has received approval from the US Food and Drug Administration (FDA) for AUBAGIO (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).
To the Editor: Tickborne relapsing fevers caused by Borrelia species are characterized by [greater than or equal to] 1 recurrent episodes of fever accompanied by headache, myalgia, arthralgia, abdominal pain, and eventually by hepatic or neurologic manifestations.
Regardless of age, patients with relapsing polychondritis (systemic chondromalacia or polychondropathy) have at least one of eight progressively degenerative changes: (1) recurrent bilateral auricular chondritis, (2) inflammatory polyarthritis, (3) nasal chondritis, (4) ocular inflammation, (5) tracheal chondritis, (6) laryngeal chondritis, (7) cochlear damage, and (8) vestibular damage.
And among relapsing patients, the difference was 40% lower with the drug.
An immune-suppressing agent for reducing neurologic disability and/ or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis.
TG Therapeutics announced results from the Phase 2 multicenter trial of TG-1101, the company's novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis.